financetom
Business
financetom
/
Business
/
Jury says Musk misled Twitter investors before 2022 buyout, Bloomberg News reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Jury says Musk misled Twitter investors before 2022 buyout, Bloomberg News reports
Mar 20, 2026 3:34 PM

March 20 (Reuters) - A jury has concluded Elon Musk defrauded Twitter investors when he disparaged the company in 2022 in an effort to buy the social media platform for a lower price than his original $44 billion bid, Bloomberg News reported on Friday.

Jurors in federal court in San Francisco found on Friday that Musk intentionally misled Twitter shareholders when he tweeted the social media network, which was later renamed X, had too many fake accounts and tried to back out of the deal, the report added.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Universal Music Group tops revenue forecasts as Taylor Swift boosts sales
Universal Music Group tops revenue forecasts as Taylor Swift boosts sales
Oct 30, 2025
(Reuters) -Universal Music Group on Thursday reported third-quarter revenue above market expectations with Taylor Swift's new release boosting physical album sales. The world's biggest music label, which also counts South Korean boy band BTS in its portfolio, said quarterly revenue grew 5% year-on-year to 3 billion euros ($3.5 billion), topping the 2.95 billion average analyst forecast provided by LSEG. Adjusted...
Bristol Myers' New Treatments Drive Q3 Beat — And The Company's Raising Its Outlook
Bristol Myers' New Treatments Drive Q3 Beat — And The Company's Raising Its Outlook
Oct 30, 2025
Bristol Myers Squibb Co. ( BMY ) reported third-quarter 2025 revenues of $12.22 billion on Thursday, beating the consensus of $11.81 billion, a 3% increase year over year. Growth Portfolio revenues of $6.9 billion increased 18%, or 17% Ex-FX. Revenue growth was primarily driven by the immuno-oncology portfolio, Reblozyl, Camzyos, and Breyanzi. Also Read: Bristol Myers Expands Cell Therapy Portfolio With...
Baxter Trims Annual Outlook Again, Stock Hits 52-Week
Baxter Trims Annual Outlook Again, Stock Hits 52-Week
Oct 30, 2025
Baxter International Inc. ( BAX ) stock hit a 52-week low on Thursday, after the company again lowered its 2025 guidance. BAX stock is at key technical levels. See the trading setup here Baxter reported a third-quarter adjusted EPS of 69 cents, surpassing the management guidance of 58-62 cents and the Wall Street estimate of 60 cents. The medical device maker...
BRIEF-Globalstar Draws SpaceX Interest In Sale Process - Bloomberg News
BRIEF-Globalstar Draws SpaceX Interest In Sale Process - Bloomberg News
Oct 30, 2025
Oct 30 (Reuters) - * GLOBALSTAR DRAWS SPACEX INTEREST IN SALE PROCESS - BLOOMBERG NEWS Source text: https://tinyurl.com/5xrrvb4b Further company coverage: ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved